Abstract Background and Objective Little is understood about neonatal pharmacokinetics
immediately after delivery and during the first days of life following intrauterine exposure to …

Background Predicting drug pharmacokinetics in pregnant women including placental drug
transfer remains challenging. This study aimed to develop and evaluate maternal–fetal …

Antiretroviral therapy during pregnancy reduces the risk of vertical HIV‐1 transmission.
However, drug dosing is challenging as pharmacokinetics (PK) may be altered during …

Maternofoetal physiologically-based pharmacokinetic models integrating multi-
compartmental maternal and foetal units were developed using Simbiology® to estimate …

Background Concerns over maternal and fetal drug exposure during pregnancy highlight
the need for improved understanding of drug distribution to the fetus through the placental …

Background Fetal antiretroviral exposure is usually derived from the cord-to-maternal
concentration ratio. This static parameter does not provide information on the …

AIMS Pregnant women can be exposed to numerous drugs during the gestational period.
For obvious ethical reasons, in vivo studies of fetal exposure to drugs are limited. Information …

Pregnancy-induced changes in plasma pharmacokinetics of many antiretrovirals (ARV) are
well-established. Current knowledge about the extent of ARV exposure in lymphoid tissues …

Background: While physiologically based pharmacokinetic (PBPK) models generally predict
pharmacokinetics in pregnant women successfully, the confidence in predicting fetal …

Pregnancy is associated with physiological changes that may impact drug pharmacokinetics
(PK). The goals of this study were to build maternal‐fetal physiologically based …